Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 01, 2026 06:40 ET | Source: Research and Markets

Liposomal Doxorubicin Market Insights Report 2026: Cancer Incidence Surge Fuels Market Growth, Asia-Pacific Emerges as Fastest-Growing Region

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Liposomal Doxorubicin Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights into...
April 01, 2026 06:37 ET | Source: Research and Markets

Doxorubicin Market Outlook 2026-2030 & 2035: Predicted to Surge to $2 Billion by 2030, Bolstered by Expanding Access to Cancer Care

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Doxorubicin Market Report 2026" has been added to ResearchAndMarkets.com's offering. This analysis provides a comprehensive perspective on the...
March 31, 2026 07:32 ET | Source: Research and Markets

Ovarian Cancer Drugs Market Outlook Report 2026-2030 Featuring Strategic Analysis of AstraZeneca, Roche, Bristol-Myers Squibb Company, Clovis Oncology, Pfizer and Other Key Players

Dublin, March 31, 2026 (GLOBE NEWSWIRE) -- The "Ovarian Cancer Drugs Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report delivers a comprehensive analysis, covering...
June 24, 2025 04:00 ET | Source: AKAMPION

Thermosome Reports Encouraging Clinical Data of THE001 in Advanced Soft Tissue Sarcomas

Heat-triggered release mechanism unequivocally confirmedFavorable safety profile with good tolerability Signs of encouraging clinical activity in heavily pre-treated patients including meaningful...
May 12, 2025 04:00 ET | Source: AKAMPION

Thermosome Receives U.S. Orphan Drug Designation for Lead Compound THE001, Expands Patent Estate

ODD granted for the treatment of soft tissue sarcomas (STS)Thermosome adds 4 patents to its growing patent estate Munich, Germany – May 12, 2025 – Thermosome, a drug development company focused on...
February 10, 2025 06:28 ET | Source: Research and Markets

Doxorubicin Global Industry Report 2025 - Doxorubicin Market Projected to Reach US$1.7 Billion by 2030

Dublin, Feb. 10, 2025 (GLOBE NEWSWIRE) -- The "Doxorubicin - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Doxorubicin was valued at...
January 13, 2025 11:54 ET | Source: Research and Markets

Liposomal Doxorubicin Market Research and Forecast Report 2024-2032: Growing Investments and Collaborations, Personalised Medicine Trends, Market Penetration in Emerging Economies

Dublin, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The "Liposomal Doxorubicin Market Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering.The global liposomal...
December 04, 2024 04:00 ET | Source: AKAMPION

Thermosome Initiates Final Dose Level in Phase I Trial of Lead Compound THE001

Independent Data Safety Monitoring Board declared dose level 2 as safe and recommended escalation to ﬁnal dose level 3 Munich, Germany – December 4, 2024 – Thermosome, a drug development company...
November 19, 2024 04:00 ET | Source: AKAMPION

Thermosome Presents Encouraging Initial Clinical Data from Phase I Trial of Lead Compound THE001

THE001 safe and well tolerated in first two dose level, demonstrating encouraging signs of clinical activityData presented at The Connective Tissue Oncology Society (CTOS) Annual Meeting 2024 Munich,...
November 07, 2024 08:04 ET | Source: Research and Markets

Liposomal Doxorubicin Market Report 2024-2032: Innovative Liposomal Formulations Pave the Way for Safer and More Effective Cancer Treatments

Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The "Liposomal Doxorubicin Market Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering.The global liposomal...